VBA delay - the analyst's view
Progress on value-based assessment has been slow and, after a three-month consultation, it’s clear that no consensus has emerged, with NICE wisely deciding that further consideration is required. - News - PharmaTimes
by Hilary Thomas, partner at KPMG
https://www.pharmatimes.com/news/vba_delay_-_the_analysts_view_1002687